EUCTR2011-005496-17-ES进行中（未招募）1 期
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 703
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female patients 18 years of age or older.
- •2. Multiple myeloma diagnosed according to standard criteria either currently or at the time of initial diagnosis.
- •NOTE: The initial diagnosis must be symptomatic MM, although the relapsed disease does not need to be symptomatic.
- •3.Patients must have measurable disease defined by at least 1 of the following 3 measurements:
- •-Serum M-protein >= 1 g/dL (>= 10 g/L).
- •-Urine M-protein >= 200 mg/24 hours.
- •-Serum free light chain assay: involved free light chain level >=10 mg/dL (>= 100 mg/L), provided that the serum free light chain ratio is abnormal.
- •4.Patients with relapsed and/or refractory MM who have received 1 to 3 prior therapies.
- •NOTE: This patient population includes the following 3 categories of patients:
- •-Patients who relapsed from their previous treatment(s) but were not refractory to any previous treatment.
- •-Patients who were refractory to all lines of previous treatment(s) (ie, patients who have never responded to any therapies received).
- •-Patients who were relapsed from at least 1 previous treatment AND additionally were refractory to at least 1 previous treatment. For the purposes of this study, refractory disease is defined as disease progression on treatment or progression within 60 days after the last dose of a given therapy.
- •A line of therapy is defined as 1 or more cycles of a planned treatment program. This may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance is considered 1 line of therapy.
- •Autologous and allogenic transplants are permitted.
- •5.Patients must meet the following clinical laboratory criteria:
- •-Absolute neutrophil count (ANC) >= 1,000/mm3 and platelet count >= 75,000/mm3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days prior to randomization.
- •-Total bilirubin <=1.5 X the upper limit of the normal range (ULN).
- •-Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3 X ULN.
- •-Calculated creatinine clearance >= 30 mL/min
- •NOTE: Patients with creatinine clearance of 30 to 50 mL/min will
- •receive lenalidomide at a reduced dose (10 mg), which may
- •subsequently be increased if well tolerated and no response.
- •6.ECOG performance status of 0, 1, or 2.
- •7.Patients who received prior allogenic transplant must have no active
- •graft-versus-host disease (GVHD).
- •8.Female patients who:
- •-Are postmenopausal for at least 24 months before the screening visit,
- •-Are surgically sterile, OR
- •-If they are of childbearing potential, agree to practice 2 effective
- •methods of contraception, at the same time, from at least 28 days before
- •starting study drug through 30 days after the last dose of study
- •treatment, OR agree to completely abstain from heterosexual
排除标准
- •1. Patient was refractory to lenalidomide or proteasome inhibitor-based therapy at any line.
- •NOTE: Refractory disease defined as disease progression on treatment or progression within 60 days after the last dose of a given therapy.
- •Patients who progress after 60 days from the last dose of a given therapy will be considered relapsed and are eligible for inclusion in the study. Patients who were refractory to thalidomide-based therapy are eligible.
- •2. Female patients who are lactating or pregnant.
- •3. Failure to have fully recovered (ie, < Grade 1 toxicity) from the effects of prior chemotherapy regardless of the interval since last treatment.
- •4. Major surgery within 14 days before randomization.
- •5. Radiotherapy within 14 days before randomization.
- •6. Central nervous system involvement.
- •7. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before randomization.
- •8. Diagnosis of Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome.
- •9. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
- •10. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John?s wort within 14 days before randomization in the study.
- •11. Ongoing or active systemic infection, active hepatitis B virus infect, active hepatitis C infection, or known human immunodeficiency virus (HIV) positive.
- •12. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
- •13. Psychiatric illness/social situation that would limit compliance with study requirements.
- •14. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
- •15. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
- •16. Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
研究者
相似试验
进行中（未招募）
1 期
To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.Relapsed and/or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2011-005496-17-PLMillennium Pharmaceuticals, Inc.703
进行中（未招募）
1 期
To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.Relapsed and/or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2011-005496-17-BEMillennium Pharmaceuticals, Inc.703
未知
3 期
A Phase 3, Double-Blind Study of TAK-438 (20 mg) in the Treatment of Erosive EsophagitisJPRN-jRCT2080221567TAKEDA PHARMACEUTICAL COMPANY LTD.400
进行中（未招募）
1 期
To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment.Relapsed and/or Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2011-005496-17-CZMillennium Pharmaceuticals, Inc.703
未知
3 期
A Phase 3, Double-Blind Study of TAK-438 (10 mg or 20 mg) in the Maintenance Treatment of Erosive EsophagitisErosive esophagitisJPRN-jRCT2080221621TAKEDA PHARMACEUTICAL COMPANY LTD.600